QRG Capital Management Inc. raised its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 17.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,691 shares of the medical research company’s stock after purchasing an additional 2,184 shares during the period. QRG Capital Management Inc.’s holdings in Natera were worth $2,938,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also modified their holdings of the company. Coatue Management LLC boosted its stake in shares of Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares during the period. Wellington Management Group LLP increased its stake in Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the period. Norges Bank acquired a new stake in shares of Natera in the 4th quarter worth $372,398,000. JPMorgan Chase & Co. lifted its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Natera
In related news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total value of $818,700.00. Following the completion of the sale, the insider directly owned 134,643 shares in the company, valued at approximately $36,744,074.70. The trade was a 2.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 178,872 shares of company stock worth $39,627,696 over the last three months. Company insiders own 5.05% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Report on NTRA
Natera Price Performance
Shares of NASDAQ NTRA traded down $1.85 on Tuesday, hitting $281.95. The company’s stock had a trading volume of 382,028 shares, compared to its average volume of 1,374,239. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $288.04. The company has a market capitalization of $40.38 billion, a price-to-earnings ratio of -173.10 and a beta of 1.51. The stock has a 50 day moving average of $221.45 and a 200-day moving average of $217.64.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
- Five stocks we like better than Natera
- Silicon Starvation: Amazon Feasts on Legacy GPUs
- GE Vernova’s Power Surge Turns the Grid Into an AI Trade
- Orbiting Capital: Lawmakers Buy SpaceX Ahead of Index Inclusion
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
